

O I P E
MAR 15 2002
JC171

COPY OF PAPERS
ORIGINALLY FILED

ALLIA.143CP3

PATENT
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : H. Zaghouani) Group Art Unit: 1644
Appl. No. : 09/873,901)
Filed : June 4, 2001)
For : COUPLING OF PERIPHERAL)
TOLERANCE TO)
ENDOGENOUS IL-10)
PROMOTES EFFECTIVE)
MODULATION OF T CELLS)
AND AMELIORATES)
AUTOIMMUNE DISEASE)
Examiner : Unknown)

I hereby certify that this correspondence and all
marked attachments are being deposited with the
United States Postal Service as first-class mail in an
envelope addressed to: United States Patent and
Trademark Office, P.O. Box 2327, Arlington, VA
22202, on

March 11, 2002
(Date)
Daniel Hart
Daniel Hart, Reg. No. 40,637

HJB

JW
4/30/02

RECEIVED
MAR 19 2002
TECH CENTER 1600/2900

SUPPLEMENTAL PRELIMINARY AMENDMENT

United States Patent and Trademark Office
P. O. Box 2327
Arlington, VA 22202

Dear Sir:

Prior to the examination of the above-identified application on the merits, please amend the application as follows:

IN THE CLAIMS:

Please cancel Claims 8, 9, 23, and 24.

Please amend Claims 1, 10, 19, 49, 64, and 65 as follows:

B1
1. (Amended) A composition comprising an immunoglobulin or portion thereof linked to an antigen associated with an autoimmune disease, wherein said composition is capable of crosslinking Fc receptors present on the cell surfaces of antigen presenting cells.

B2
10. (Amended) The composition of Claim 1, wherein said antigen is associated with an autoimmune disease selected from the group consisting of multiple sclerosis, lupus, rheumatoid arthritis, scleroderma, insulin-dependent diabetes and ulcerative colitis.